Comparative Pharmacology
Head-to-head clinical analysis: Q PAM versus SILODOSIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: Q PAM versus SILODOSIN.
Q-PAM vs SILODOSIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Q-PAM is a quaternary ammonium neuromuscular blocking agent that competitively blocks acetylcholine at nicotinic receptors at the neuromuscular junction, causing depolarizing neuromuscular blockade.
Silodosin is a highly selective antagonist of alpha-1A adrenergic receptors located primarily in the prostate, bladder base, and proximal urethra. Blockade of these receptors relaxes smooth muscle in these tissues, reducing urinary outflow resistance and improving symptoms of benign prostatic hyperplasia (BPH). It has minimal affinity for alpha-1B receptors, thereby reducing the risk of orthostatic hypotension compared to non-selective alpha blockers.
100 mg orally twice daily
8 mg orally once daily with a meal.
None Documented
None Documented
Clinical Note
moderateSilodosin + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Silodosin."
Clinical Note
moderateSilodosin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Silodosin."
Clinical Note
moderateSilodosin + Tranilast
"Silodosin may increase the hypotensive activities of Tranilast."
Clinical Note
moderateSilodosin + Prednisone
Terminal half-life: 8-12 hours (mean 10 h) in healthy adults. Prolonged in renal impairment (up to 24 h in CrCl <30 mL/min); no dose adjustment needed in mild-moderate hepatic impairment.
Terminal half-life: 11-13 hours; allows once-daily dosing; prolongation in severe renal impairment
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total clearance ~12 L/h.
Renal (33.5% as unchanged drug, 64.3% as metabolites); fecal (<5%)
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker
"The serum concentration of Prednisone can be increased when it is combined with Silodosin."